Nanobodies and Cancer: Current Status and New Perspectives

References

• Teillaud JL. From whole monoclonal antibodies to single domain antibodies: Think Small. In: Dirk Saerens and Serge Muyldermans, editors. Single Domain Antibodies: Methods and Protocols, Methods in Molecular Biology. Vol. 911. New Jersey (USA) © Springer Science+Business Media, LLC; 2012. doi:10.1007/978-1-61779-968-6_1.
   Google Scholar
• Revets H, De Baetselier P, Muyldermans S. Nanobodies as novel agents for cancer therapy. Expert Opin Biol Ther. 2005;5:111–124. doi:10.1517/14712598.5.1.111.
   PubMed Web of Science ®Google Scholar
• Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB, Bendahman N, Hamers R. Naturally occurring antibodies devoid of light chains. Nature. 1993;363:446–448. doi:10.1038/363446a0.
   PubMed Web of Science ®Google Scholar
• Muyldermans S. Single domain camel antibodies: current status. Rev Mol Biotechnol. 2001;74:277–302. doi:10.1016/S1389-0352(01)00021-6.
   Google Scholar
• Wolfson W. Ablynx makes nanobodies from Llama bodies. Chem Biol. 2006;13:1243–1244. doi:10.1016/j.chembiol.2006.12.003.
   PubMedGoogle Scholar
• Daley LP, Gagliardo LF, Duffy MS, Smith MC, Appleton JA. Application of monoclonal antibodies in functional and comparative investigations of heavy-chain immunoglobulins in new word camelids. Clin Diagn Lab Immunol. 2005;12:380–386.
   PubMedGoogle Scholar
• Maas DR, Sepulveda J, Pernthaner A, Shoemaker CB. Alpaca (Lama pacos) as a convenient source of recombinant camelid heavy chain antibodies (VHHs). J Immunol Methods. 2007;324:13–25 doi:10.1016/j.jim.2007.04.008.
   PubMed Web of Science ®Google Scholar
• Schmitz KR, Bagchi A, Roovers RC, van Bergen en Henegouwen PM, Ferguson KM. Structural evaluation of EGFR inhibition mechanisms for nanobodies/VHH domains. Structure. 2013;21:1214–1224. doi:10.1016/j.str.2013.05.008.
   PubMed Web of Science ®Google Scholar
• Krah S, Schröter C, Zielonka S, Empting M, Valldorf B, Harald K. Single-domain antibodies for biomedical applications. Immunopharmacol Immunotoxicol. 2015;38:21–8. doi:10.3109/08923973.2015.1102934.
   PubMed Web of Science ®Google Scholar
• Greenberg AS, Avila D, Hughes M, Hughes A, McKinney EC, Flajnik MF. A New antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks. Nature. 1995;374:168–173. doi:10.1038/374168a0.
   PubMed Web of Science ®Google Scholar
• Nuttall SD, Krishnan UV, Hattarki M, DeGori R, Irving RA, Hudson PJ. Isolation of the new antigen receptor from wobbegong sharks, and use as a scaffold for the display of protein loop libraries. Mol Immunol. 2001;38:313–326. doi:10.1016/S0161-5890(01)00057-8.
   PubMed Web of Science ®Google Scholar
• Nuttall SD, Humberstone KS, Krishnan UV, Carmichael JA, Doughty L, Hattarki M, Coley AM, Casey JL, Anders RF, Foley M, et al. Selection and affinity maturation of IgNAR variable domains targeting Plasmodium falciparum AMA1. Proteins. 2004;55:187–197. doi:10.1002/prot.20005.
   PubMed Web of Science ®Google Scholar
• Zielonka S, Empting M, Grzeschik J, Könning D, Barelle CJ, Kolmar H. Structural insights and biomedical potential of IgNAR scaffolds from sharks. MAbs. 2015;7:15–25. doi:10.4161/19420862.2015.989032.
   PubMed Web of Science ®Google Scholar
• Barelle C, Gill DS, Charlton K. Shark novel antigen receptors-the next generation of biologic therapeutics? Adv Exp Med Biol. 2009;655:49–62. doi:10.1007/978-1-4419-1132-2_6.
   PubMed Web of Science ®Google Scholar
• Stanfield RL, Dooley H, Flajnik MF, Wilson IA. Crystal structure of a shark single-domain antibody V region in complex with lysozyme. Science. 2004;305:1770–1773. doi:10.1126/science.1101148.
   PubMed Web of Science ®Google Scholar
• Dooley H, Stanfield RL, Brady RA, Flajnik MF. First molecular and biochemical analysis of in vivo affinity maturation in an ectothermic vertebrate. Proc Natl Acad Sci USA. 2006;103:1846–1851. doi:10.1073/pnas.0508341103.
   PubMed Web of Science ®Google Scholar
• Smolarek D, Bertrand O, Czerwinski M. Variable fragments of heavy chain antibodies (VHHs): a new magic bullet molecule of medicine? Postepy Hig Med Dosw (online). 2012;66:348–358. doi:10.5604/17322693.1000334.
   PubMedGoogle Scholar
• Baral TN, MacKenzie R, Ghahroudi MA. Single-domain antibodies and their utility. Curr Protocols Immunol. 2013;103:1–57. doi:10.1002/0471142735.im0217s103.
   PubMedGoogle Scholar
• Lauwereys M, Arbabi Ghahroudi M, Desmyter A, Kinne J, Hölzer W, De Genst E, Wyns L, Muyldermans S. Potent enzyme inhibitors derived from dromedary heavy-chain antibodies. EMBO J. 1998;17:3512–3520. doi:10.1093/emboj/17.13.3512.
   PubMed Web of Science ®Google Scholar
• De Genst E, Silence K, Decanniere K, Conrath K, Loris R, Kinne J, Muyldermans S, Wyns L. Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies. Proc Natl Acad Sci U.S.A. 2006;103:4586–4591 doi:10.1073/pnas.0505379103.
   PubMed Web of Science ®Google Scholar
• De Meyer T, Muyldermans S, Depicker A. Nanobody-based products as research and diagnostic tools. Trends Biotechnol. 2014;32(5):263–270. doi:10.1016/j.tibtech.2014.03.001.
   PubMed Web of Science ®Google Scholar
• Baral TN, Murad Y, Nguyen TD, Iqbal U, Zhang J. Isolation of functional single domain antibody by whole cell immunization: implications for cancer treatment. J. Immunol Methods. 2011;371:70–80. doi:10.1016/j.jim.2011.06.017.
   PubMed Web of Science ®Google Scholar
• Kijanka M, Dorresteijn B, Oliveira S, van Bergen en Henegouwen PMP. Nanobody-based cancer therapy of solid tumors. Nanomedicine (Lond.) 2015;10(1):161–174 doi:10.2217/nnm.14.178.
   PubMed Web of Science ®Google Scholar
• Vincke C, Gutiérrez C, Wernery U, Devoogdt N, Hassanzadeh-Ghassabeh G, Muyldermans S. Generation of single domain antibody fragments derived from camelids and generation of manifold constructs. Methods Mol Biol. 2012;907:145–176 doi:10.1007/978-1-61779-974-7_8.
   PubMedGoogle Scholar
• Peyvandi F, Callewaert F. Caplacizumab for acquired thrombotic thrombocytopenic Purpura. N Engl J Med. 2016;374(25):2497–2498 doi:10.1056/NEJMc1603180.
   PubMed Web of Science ®Google Scholar
• Scully M, Cataland SR, Peyvandi F, Coppo P, Knöbl P, Kremer Hovinga JA, et al. Results of the randomized, double-blind, placebo-controlled, Phase 3 hercules study of caplacizumab in patients with acquired thrombotic thrombocytopenic purpura. ASH meeting 59th Annual Meeting Atlanta GA December 9–12 2017 Paper109057
   Google Scholar
• Kratz F, Elsadek B. Clinical impact of serum proteins on drug delivery. J Control Release. 2012;161(2):429–445. doi:10.1016/j.jconrel.2011.11.028.
   PubMed Web of Science ®Google Scholar
• Van Audenhove I, Gettemans J. Nanobodies as versatile tools to understand, diagnose, visualize and treat cancer. EBioMed. 2016;8:40–48 doi:10.1016/j.ebiom.2016.04.028.
   PubMed Web of Science ®Google Scholar
• He B, Chadburn A. Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL. J Immunol. 2004;172:3268–3279. doi:10.4049/jimmunol.172.5.3268.
   PubMed Web of Science ®Google Scholar
• Stohl W. Biologic differences between various inhibitors of the BLyS/BAFFpathway: should we expect differences between belimumab and other inhibitors in development? Curr Rheumatol Rep. 2012;14 (4):303–309. doi:10.1007/s11926-012-0254-6.
   PubMed Web of Science ®Google Scholar
• Häsler J, Flajnik MF, Williamsd G, Walsha FS, Rutkowskia JL. VNAR single-domain antibodies specific for BAFF inhibit B cell development by molecular mimicry. Mol Immunol. 2016;75:28–37 doi:10.1016/j.molimm.2016.05.009.
   PubMed Web of Science ®Google Scholar
• Wu W, Li S, Zhang W, Sun J, Ren G, Dong Q. A novel VHH antibody targeting the B Cell-activating factor for B-Cell Lymphoma. Int J Mol Sci. 2014;15:9481–9496; doi:10.3390/ijms15069481.
   PubMed Web of Science ®Google Scholar
• Wild J, Schmiedel BJ, Maurer A, Raab S, Prokop L, Stevanović S, Dörfel D, Schneider P, Salih HR. Neutralization of (NK-cell-derived) B-cell activating factor by Belimumab restores sensitivity of chronic lymphoid leukemia cells to direct and Rituximab-induced NK lysis. Leukemia. 2015;29 (8):1676–1683. doi:10.1038/leu.2015.50.
   PubMed Web of Science ®Google Scholar
• Fang T, Duarte JN, Ling J, Li Z, Guzman JS, Ploegh HL. Structurally defined aMHC-II Nanobody–Drug conjugates: A Therapeutic and Imaging System for B-cell lymphoma. Angew Chem Int Ed. 2016;55:2416–2420 doi:10.1002/anie.201509432.
   PubMed Web of Science ®Google Scholar
• Li T, Qi S, Unger M, Hou YN, Deng QW, Liu J, Lam CM, Wang XW, Xin D, Zhang P, et al. Immuno-targeting the multifunctional CD38 using nanobody. Scientific Reports. 2016;6:27055 doi:10.1038/srep27055.
   PubMed Web of Science ®Google Scholar
• Borset M, Hjorth-Hansen H, Seidel C, Sundan A, Waage A. Hepatocyte growth factor and its receptor c-MET in multiple myeloma. Blood. 1996;88(10):3998–4004.
   PubMedGoogle Scholar
• Slørdahl TS, Denayer T, Moen SH, Standal T, Børset M, Ververken C, Rø TB. Anti-c-MET Nanobody® – A new potential drug in multiple myeloma treatment. Eur J Haematol. 2013;91:399–410 doi:10.1111/ejh.12185.
   PubMed Web of Science ®Google Scholar
• Lemaire M, D'Huyvetter M, Lahoutte T, Van Valckenborgh E, Menu E, De Bruyne E, Kronenberger P, Wernery U, Muyldermans S, Devoogdt N, et al. Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic Nanobodies. Leukemia. 2014;28:444–447 doi:10.1038/leu.2013.292.
   PubMed Web of Science ®Google Scholar
• Van de Water JAJM, Bagci-Onder T, Agarwal AS, Wakimoto H, Roovers RC, Zhu Y, et al. Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects. PNAS. 2012;41:16642–16647. doi:10.1073/pnas.1202832109.
   Google Scholar
• Roodink I, Franssen M, Zuidscherwoude M, Verrijp K, van der Donk T, Raats J, Leenders WP. Isolation of targeting nanobodies against co-opted tumor vasculature. Lab Invest. 2010;90:61–67 doi:10.1038/labinvest.2009.107.
   PubMed Web of Science ®Google Scholar
• Iqbal U, Albaghdadi H, Luo Y, Arbabi M, Desvaux C, Veres T, Stanimirovic D, Abulrob A. Molecular imaging of glioblastoma multiforme using anti-insulin-like growth factor-binding protein-7 single-domain antibodies. Br J Cancer. 2010;103:1606–1616. doi:10.1038/sj.bjc.6605937.
   PubMed Web of Science ®Google Scholar
• Jovcevska I, Zupanec N, Kocevar N, Cesselli D, Podergajs N, Stokin CL, et al. TRIM28 and b-actin identified via nanobody-based reverse proteomics approach as possible human glioblastoma biomarkers. PLoS One. 2014;9(11):e113688. doi:10.1371/journal.pone.0113688.
   PubMed Web of Science ®Google Scholar
• Zhou J, Fan X, Chen N, Zhou F, Dong J, Nie Y, Fan D. Identification of CEACAM5 as a biomarker for prewarning and prognosis in gastric cancer. J Histochem Cytochem. 2015;63:922–930. doi:10.1369/0022155415609098.
   PubMed Web of Science ®Google Scholar
• Duffy MJ. Carcinoembryonic antigen as a marker for colorectal cancer: it is clinically useful? Clin Chem. 2001;47:624–630.
   PubMed Web of Science ®Google Scholar
• Behar G, Chames P, Teulon I, Cornillon A, Alshoukr F, Roquet F, Pugnière M, Teillaud JL, Gruaz-Guyon A, Pèlegrin A, et al. Llama single-domain antibodies directed against nonconventional epitopes of tumor-associated carcinoembryonic antigen absent from nonspecific cross-reacting antigen. FEBS J. 2009;276:3881–3893. doi:10.1111/j.1742-4658.2009.07101.x.
   PubMed Web of Science ®Google Scholar
• Kuroki M, Matsuo Y, Kinugasa T, Matsuoka Y. Three different NCA species, CGM6/CD67, NCA-95, and NCA-90 are comprised in the major 90 to 100 kDa band of granulocyte NCA detectable upon SDS-polyacrylamide gel electrophoresis. Biochem Biophys Res Commun. 1992;182:501–506. doi:10.1016/0006-291X(92)91760-N.
   PubMed Web of Science ®Google Scholar
• Blumenthal RD, Hansen HJ, Goldenberg DM. Inhibition of adhesion, invasion, and metastasis by antibodies targeting CEACAM6 (NCA-90) and CEACAM5 (carcinoembryonic antigen). Cancer Res. 2005;65:8809. doi:10.1158/0008-5472.CAN-05-0420.
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Witzig TE, Adjei AA. Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin. 2005;55:178–194. doi:10.3322/canjclin.55.3.178.
   PubMed Web of Science ®Google Scholar
• Huet HA, Growney JD, Johnson JA, Li J, Bilic S, Ostrom L, Zafari M, Kowal C, Yang G, Royo A, et al. Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction. mAbs. 2014;6:1560–1570 doi:10.4161/19420862.2014.975099.
   PubMed Web of Science ®Google Scholar
• Papadopoulos KP, Isaacs R, Bilic S, Kentsch K, Huet HA, Hofmann M, Rasco D, Kundamal N, Tang Z, Cooksey J, et al. Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody® targeting the DR5 receptor. Cancer Chemother Pharmacol. 2015;75(5):887–895. doi:10.1007/s00280-015-2712-0.
   PubMed Web of Science ®Google Scholar
• Feng M, Gao W, Wang R, Chen W, Man YG, Figg WD, Wang XW, Dimitrov DS, Ho M. Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. PNAS. 2013;110:1083–1091. doi:10.1073/pnas.1217868110.
   PubMed Web of Science ®Google Scholar
• Shaker GH, Melake NA. Use of the single cell gel electrophoresis (comet assay) for comparing apoptotic effect of conventional antibodies versus nanobodies. Saudi Pharmaceutical J. 2012;20:221–227. doi:10.1016/j.jsps.2011.11.004.
   PubMed Web of Science ®Google Scholar
• Fekrazad R, Hakimiha N, Farokhi E, Rasaee MJ, Ardestani MS, Kalhori KA, Sheikholeslami F. Treatment of oral squamous cell carcinoma using anti-HER2 immunonanoshells. Int J Nanomed. 2011;6:2749–2755
   PubMed Web of Science ®Google Scholar
• Tian B, Wong WY, Hegmann E, Gaspar K, Kumar P, Chao H. Production and characterization of a camelid single domain antibody−urease enzyme conjugate for the treatment of cancer. Bioconjugate Chem.
   Google Scholar
• McMurphy T, Xiao R, Magee D, Slater A, Zabeau L, Tavernier J, Cao L. The anti-tumor activity of a neutralizing nanobody targeting leptin receptor in a mouse model of melanoma. PLoS One. 2014;9(2):e89895. doi:10.1371/journal.pone.0089895.
   PubMed Web of Science ®Google Scholar
• Yu F, Wang Y, Xiao Y, He Y, Luo C, Duan D, Li C, S5 X, Xiang T. RP215 single chain fragment variable and single domain recombinantantibodies induce cell cycle arrest at G0/G1 phase in breast cancer. Mol Immunol. 2014;59:100–109 doi:10.1016/j.molimm.2014.01.007.
   PubMed Web of Science ®Google Scholar
• Turini M, Chames P, Bruhns P, Baty D, Kerfelec B. A FcgammaRIII-engaging bispecific antibody expands the range of HER2-expressing breast tumors eligible to antibody therapy. Oncotarget. 2014;5:5304–5319. doi:10.18632/oncotarget.2093.
   PubMedGoogle Scholar
• Li L, He P, Zhou C, Jing L, Dong B, Chen S, Zhang N, Liu Y, Miao J, Wang Z, et al. A novel bispecific antibody, S-Fab, induces potent cancer cell killing. J Immunother. 2015;38:350–356. doi:10.1097/CJI.0000000000000099.
   PubMed Web of Science ®Google Scholar
• Kazemi T, Younesi V, Jadidi-Niaragh F, Yousefi M. Immunotherapeutic approaches for cancer therapy:An update review. Artif Cells Nanomed Biotechnol. 2016;44:769–779.
   PubMed Web of Science ®Google Scholar
• Gray MA, Tao RN, DePorter SM, Spiegel DA, McNaughton BR. A nanobody activation immunotherapeutic that selectively destroys HER2-positive breast cancer cells. Chem Bio Chem. 2016;17:155–158 doi:10.1002/cbic.201500591.
   Google Scholar
• Van Impe K, Bethuyne J, Cool S, Impens F, Ruano-Gallego D, De Wever O, Vanloo B, Van Troys M, Lambein K, Boucherie C, et al. A nanobody targeting the F-actin capping protein CapG restrains breast cancer metastasis. Breast Cancer Res. 2013;15:116 doi:10.1186/bcr3585.
   Web of Science ®Google Scholar
• Ramsey DM, McAlpine SR. Halting metastasis through CXCR4 inhibition. Bioorganic Med Chem Letters. 2013;23:20–25 doi:10.1016/j.bmcl.2012.10.138.
   PubMed Web of Science ®Google Scholar
• Maussang D, Mujić-Delić A, Descamps FJ, Stortelers C, Vanlandschoot P, Stigter-van Walsum M, Vischer HF, van Roy M, Vosjan M, Gonzalez-Pajuelo M, et al. Llama-derived single Variable Domains (Nanobodies) directed against chemokine receptor CXCR7 reduce head and neck cancer cell growth in Vivo. J Biol Chem. 2013;41:29562–29572 doi:10.1074/jbc.M113.498436.
   Google Scholar
• Muyldermans S, Baral TN, Retamozzo VC, De Baetselier P, De Genst E, Kinne J, Leonhardt H, Magez S, Nguyen VK, Revets H, et al. Camelid immunoglobulins and nanobody technology. Vet Immunol Immunopathol. 2009;128:178–183. doi:10.1016/j.vetimm.2008.10.299.
   PubMed Web of Science ®Google Scholar
• Stijlemans B, Conrath K, Cortez-Retamozo V, Van Xong H, WynsL, Senter P, Revets H, De Baetselier P, Muyldermans S, Magez S. Efficient targeting of conserved cryptic epitopes of infectious agents by single domain antibodies. African trypanosomes as paradigm. J Biol Chem. 2004;279:1256–1261. doi:10.1074/jbc.M307341200.
   PubMed Web of Science ®Google Scholar
• Baral TN, Magez S, Stijlemans B, Conrath K, Vanhollebeke B, Pays E, Muyldermans S, De Baetselier P. Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor. Nat Med. 2006;12:580–584. doi:10.1038/nm1395.
   PubMed Web of Science ®Google Scholar
• Cortez-Retamozo V, Lauwereys M, Hassanzadeh Gh G, Gobert M, Conrath K, Muyldermans S, De Baetselier P, Revets H. Efficient tumor targeting by single-domain antibody fragments of camels. Int J Cancer. 2002;98:456–462. doi:10.1002/ijc.10212.
   PubMed Web of Science ®Google Scholar
• Abulrob A, Sprong H, Van Bergen en Henegouwen P, Stanimirovic D. The blood-brain barrier transmigrating single domain antibody: Mechanisms of transport and antigenic epitopes in human brain endothelial cells. J Neurochem. 2005;95:1201–1214. doi:10.1111/j.1471-4159.2005.03463.x.
   PubMed Web of Science ®Google Scholar
• Bell A, Wang ZJ, Arbabi-Ghahroudi M, Chang TA, Durocher Y, Trojahn U, Baardsnes J, Jaramillo ML, Li S, Baral TN, et al. Differential tumor-targeting abilities of three single-domain antibody formats. Cancer Lett. 2010;289:81–90. doi:10.1016/j.canlet.2009.08.003.
   PubMed Web of Science ®Google Scholar
• Els Conrath K, Lauwereys M, Wyns L, Muyldermans S. Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs. J Biol Chem. 2011;276:7346–7350. doi:10.1074/jbc.M007734200.
   Google Scholar
• Zhang J, Mackenzie CR. Multivalent display of single-domain antibodies. Methods Mol Biol. 2012;911:445–456.
   PubMedGoogle Scholar
• Zhang J, Tanha J, Hirama T, Khieu NH, To R, Tong-Sevinc H, Stone E, Brisson JR, MacKenzie CR. Pentamerization of single-domain antibodies from phage libraries: Anovel strategy for the rapid generation of high avidity antibody reagents. J Mol Biol. 2004;335:49–56. doi:10.1016/j.jmb.2003.09.034.
   PubMed Web of Science ®Google Scholar
• Cortez-Retamozo V, Backmann N, Senter PD, Wernery U, De Baetselier P, Muyldermans S, et al. Efficient cancer therapy with a nanobody-based conjugate. Cancer Res. 2004;64:2853–2857. doi:10.1158/0008-5472.CAN-03-3935.
   PubMed Web of Science ®Google Scholar
• van den Berg A, Dowdy SF. Protein transduction domain delivery of therapeutic macromolecules. Curr Opin Biotechnol. 2011;22(6):888–893 doi:10.1016/j.copbio.2011.03.008.
   PubMed Web of Science ®Google Scholar
• McNaughton BR, Cronican JJ, Thompson DB, Liu DR. Mammalian cell penetration, siRNA transfection, and DNA transfection by supercharged proteins. Proc Natl Sci USA. 2009;106(15):6111–6116. doi:10.1073/pnas.0807883106.
   PubMed Web of Science ®Google Scholar
• Blanco-Toribio A, Muyldermans S, Frankel G, Angel Fernandez L. Direct injection of functional single-domain antibodies from E. coli into human cells. PLoS One. 2010;5(12):e15227 doi:10.1371/journal.pone.0015227.
   PubMed Web of Science ®Google Scholar
• Coppieters K, Dreier T, Silence K, de Haard H, Lauwereys M, Casteels P, Beirnaert E, Jonckheere H, Van de Wiele C, Staelens L, et al. Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis. Arthritis and Rheumatism. 2006;54:1856–1866. doi:10.1002/art.21827.
   PubMed Web of Science ®Google Scholar
• Sarker SA, Jäkel M, Sultana S, Alam NH, Bardhan PK, Chisti MJ, Salam MA, Theis W, Hammarström L, Frenken LG. Anti-rotavirus protein reduces stool output in infants with diarrhea: a randomized placebo-controlled trial. Gastroenterology. 2013;145:740–748 doi:10.1053/j.gastro.2013.06.053.
   PubMed Web of Science ®Google Scholar
• Arbabi-Ghahroudi M, Tanha J, MacKenzie R. Prokaryotic expression of antibodies. Cancer Metastasis Rev. 2005;24:501–519 doi:10.1007/s10555-005-6193-1.
   PubMed Web of Science ®Google Scholar
• Harmsen MM, De Haard HJ. Properties, production, and applications of camelid single-domain antibody fragments. Appl Microbiol Biotechnol. 2007;77:13–22 doi:10.1007/s00253-007-1142-2.
   PubMed Web of Science ®Google Scholar
• Dumoulin M, Conrath K, Van Meirhaeghe A, Meersman F, Heremans K, Frenken LG, Muyldermans S, Wyns L, Matagne A. Single-domain antibody fragments with high conformational stability. Protein Sci. 2002;11:500–515. doi:10.1110/ps.34602.
   PubMed Web of Science ®Google Scholar
• Ewert S, Cambillau C, Conrath K, Plückthun A. Biophysical properties of camelid V(HH) domains compared to those of human V(H)3 domains. Biochemistry. 2002;41:3628–3636. doi:10.1021/bi011239a.
   PubMed Web of Science ®Google Scholar
• Dolk E, van Vliet C, Perez JM, Vriend G, Darbon H, Ferrat G, Cambillau C, Frenken LG, Verrips T. Induced refolding of a temperature denatured llame heavy-chain antibody ragment by its antigen. Proteins. 2005;59:555–564. doi:10.1002/prot.20378.
   PubMed Web of Science ®Google Scholar
• Harmsen MM, van Solt CB, van Zijderveld-van Bemmel AM, Niewold TA, van Zijderveld FG. Selection and optimization of proteolytically stable llama single-domain antibody fragments for oral immunotherapy. Appl Microbiol Biotechnol. 2006;72:544–551 doi:10.1007/s00253-005-0300-7.
   PubMed Web of Science ®Google Scholar
• Harrison RA, Hasson SS, Harmsen M, Laing GD, Conrath K, Theakston RD. Neutralisation of venom-induced haemorrhage by IgG from camels and llamas immunised with viper venom and also by endogenous, non-IgG components in camelid sera. Toxicon. 2006;47:364–368. doi:10.1016/j.toxicon.2005.10.017.
   PubMed Web of Science ®Google Scholar
• Tijink BM, Laeremans T, Budde M, Stigter-van Walsum M, Dreier T, de Haard HJ, Leemans CR, van Dongen GA. Improved tumor targeting of anti-epidermal growth factor receptor nanobodies through albumin binding: taking advantage of modular nanobody technology. Mol. Cancer Ther. 2008;7:2288–2297. doi:10.1158/1535-7163.MCT-07-2384.
   PubMed Web of Science ®Google Scholar
• Vosjan MJ, Vercammen J, Kolkman JA, Stigter-van Walsum M, Revets H, van Dongen GA. Nanobodies targeting the hepatocyte growth factor: potential new drugs for molecular cancer therapy. Mol Cancer Ther. 2012;11:1017–1025. doi:10.1158/1535-7163.MCT-11-0891.
   PubMed Web of Science ®Google Scholar
• Allegra A, Penna G, Alonci A, Rizzo V, Russo S, Musolino C. Nanoparticles in oncology: the new theragnostic molecules. Anticancer Agents Med Chem. 2011;11(7):669–686. doi:10.2174/187152011796817682.
   PubMed Web of Science ®Google Scholar
• Heukers R, Altintas I, Raghoenath S, De Zan E, Pepermans R, Roovers RC, Haselberg R, Hennink WE, Schiffelers RM, Kok RJ, et al. Targeting hepatocyte growth factor receptor (Met) positive tumor cells using internalizing nanobody-decorated albumin nanoparticles. Biomaterials. 2014;35:601–610. doi:10.1016/j.biomaterials.2013.10.001.
   PubMed Web of Science ®Google Scholar
• Zou T, Dembele F, Beugnet A, Sengmanivong L, Trepout S, Marco S, de Marco A, Li MH. Nanobody-functionalized PEG-b-PCL polymersomes and their targeting study. J Biotechnol. 2015;214:147–155. doi:10.1016/j.jbiotec.2015.09.034.
   PubMed Web of Science ®Google Scholar
• Sadeqzadeh E, Rahbarizadeh F, Ahmadvand D, Rasaee MJ, Parhamifar L, Moghimi SM. Combined MUC1-specific nanobody-tagged PEG-polyethylenimine polyplex targeting and transcriptional targeting of Bid transgene for directed killing of MUC1 over-expressing tumour cells. J Control Release. 2011;156:85–91. doi:10.1016/j.jconrel.2011.06.022.
   PubMed Web of Science ®Google Scholar
• Oliveira S, Schiffelers RM, van der Veeken J, van der Meel R, Vongpromek R, van Bergen en Henegouwen PM, et al. Downregulation of EGFR by a novel multivalent nanobody-liposome platform. J Controlled Release. 2010;145:165–175. doi:10.1016/j.jconrel.2010.03.020.
   PubMed Web of Science ®Google Scholar
• van der Meel R, Oliveira S, Altintas I, Haselberg R, van der Veeken J, Roovers RC, van Bergen en Henegouwen PM, Storm G, Hennink WE, et al. Tumor-targeted nanobullets: anti-EGFR nanobody-liposomes loaded with anti-IGF-1R kinase inhibitor for cancer treatment. J Control Release. 2012;159:281–289. doi:10.1016/j.jconrel.2011.12.027.
   PubMed Web of Science ®Google Scholar
• Talelli M, Rijcken CJ, Oliveira S, van der Meel R, van Bergen En Henegouwen PM, Lammers T, van Nostrum CF, Storm G, Hennink WE. Nanobody-shell functionalized thermosensitive core-crosslinked polymeric micelles for active drug targeting. J Control Release. 2011;151:183–192. doi:10.1016/j.jconrel.2011.01.015.
   PubMed Web of Science ®Google Scholar
• Talelli M, Oliveira S, Rijcken CJ, Pieters EH, Etrych T, Ulbrich K, van Nostrum RC, Storm G, Hennink WE, Lammers T. Intrinsically active nanobody-modified polymeric micelles for tumor-targeted combination therapy. Biomaterials. 2013;34:1255–1260. doi:10.1016/j.biomaterials.2012.09.064.
   PubMed Web of Science ®Google Scholar
• Dijkers EC, Kosterink JG, Rademaker AP, Perk LR, van Dongen GA, Bart J, de Jong JR, de Vries EG, Lub-de Hooge MN. Development and characterization of clinical-grade 89Zr-trastuzumab for HHER2/ neu immunoPET imaging. J Nud Med. 2009;50:974–978. doi:10.2967/jnumed.108.060392.
   Google Scholar
• Vaneycken I, D'huyvetter M, Hernot S, De Vos J, Xavier C, Devoogdt N, Caveliers V, Lahoutte T. Immuno-imaging using nanobodies. Curr Opin Biotechnol. 2011;22:877–881 doi:10.1016/j.copbio.2011.06.009.
   PubMed Web of Science ®Google Scholar
• Oliveira S, Heukers R, Sornkom J, Kok RJ, van Bergen En Henegouwen PM. Targeting tumors with nanobodies for cancer imaging and therapy. J Control Release. 2013;172:607–617 doi:10.1016/j.jconrel.2013.08.298.
   PubMed Web of Science ®Google Scholar
• Cuesta AM, Sainz-Pastor N, Bonet J, Oliva B, Alvarez-Vallina L. Multivalent antibodies: when design surpasses evolution. Trends Biotechnol. 2010;28:355–362 doi:10.1016/j.tibtech.2010.03.007.
   PubMed Web of Science ®Google Scholar
• Cortez-Retamozo V, Lauwereys M, Hassanzadeh Gh G, Gobert M, Conrath K, Muyldermans S, De Baetselier P, Revets H. Efficient tumor targeting by single-domain antibody fragments of camels. Int J Cancer. 2002;98:456–462. doi:10.1002/ijc.10212.
   PubMed Web of Science ®Google Scholar
• Huang L, Muyldermans S, Saerens D. Nanobodies®: proficient tools in diagnostics. Expert Rev Mol Diagn. 2010;10(6):777–785 doi:10.1586/erm.10.62.
   PubMed Web of Science ®Google Scholar
• Rothbauer U, Zolghadr K, Tillib S, Nowak D, Schermelleh L, Gahl A, Backmann N, Conrath K, Muyldermans S, Cardoso MC, et al. Targeting and tracing antigens in live cells with fluorescent nanobodies. Nat Methods. 2006;3(11):887–889. doi:10.1038/nmeth953.
   PubMed Web of Science ®Google Scholar
• Olichon A, Surrey T. Selection of genetically encoded fluorescent single domain antibodies engineered for efficient expression in Escherichia coli. J Biol Chem. 2007;282(50):36314–36320. doi:10.1074/jbc.M704908200.
   PubMed Web of Science ®Google Scholar
• van Driel PB, van der Vorst JR, Verbeek FP, Oliveira S, Snoeks TJ, Keereweer S, Chan B, Boonstra MC, Frangioni JV, van Bergen en Henegouwen PM, et al. Intraoperative fluorescence delineation of head and neck cancer with a fluorescent anti-epidermal growth factor receptor nanobody. Int J Cancer. 2014;134:2663–2673. doi:10.1002/ijc.28601.
   PubMed Web of Science ®Google Scholar
• Xavier C, Vaneycken I, D'huyvetter M, Heemskerk J, Keyaerts M, Vincke C, et al. Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 nanobodies for iPET imaging of HER2 receptor expression in cancer. J Nucl Med. 2013;54:776–784. doi:10.2967/jnumed.112.111021.
   PubMed Web of Science ®Google Scholar
• Broisat A, Hernot S, Toczek J, De Vos J RLM, Martin S, Ahmadi M, Thielens N, Wernery U, Caveliers V, et al. Nanobodies targeting mouse/human VCAM1 for the nuclear imaging of atherosclerotic lesions. Circ Res. 2012;110:927–937. doi:10.1161/CIRCRESAHA.112.265140.
   PubMed Web of Science ®Google Scholar
• Li T, Bourgeois JP, Celli S, Glacial F, Le Sourd AM, Mecheri S, Weksler B, Romero I, Couraud PO, Rougeon F, et al. Cell-penetrating anti-GFAP VHH and corresponding fluorescent fusion protein VHH–GFP spontaneously cross the blood– brain barrier and specifically recognize astrocytes: application to brain imaging. FASEB J. 2012;26:3969–3979. doi:10.1096/fj.11-201384.
   PubMed Web of Science ®Google Scholar
• Rutgers KS, Nabuurs RJ, van den Berg SA, Schenk GJ, Rotman M, Verrips CT, et al. Transmigration of b amyloid specific heavy chain antibody fragments across the in vitro blood–brain barrier. Neuroscience. 2011;190:37–42. doi:10.1016/j.neuroscience.2011.05.076.
   PubMed Web of Science ®Google Scholar
• Muruganandam A, Tanha J, Narang S, Stanimirovic D. Selection of phage-displayed llama single-domain antibodies that transmigrate across human blood-brain barrier endothelium. FASEB J. 2002;16:240–242. doi:10.1096/fj.01-0343fje.
   PubMed Web of Science ®Google Scholar
• Abulrob A, Sprong H, Van Bergen en Henegouwen P, Stanimirovic D. The blood-brain barrier transmigrating single domain antibody: mechanisms of transport and antigenic epitopes in human brain endothelial cells. J Neurochem. 2005;95:1201–1214. doi:10.1111/j.1471-4159.2005.03463.x.
   PubMed Web of Science ®Google Scholar
• Wang D, El-Amouri SS, Dai M, Kuan C-Y, Hui DY, Brady RO, Pan D. Engineering a lysosomal enzyme with a derivative of receptor-binding domain of apoE enables delivery across the blood-brain barrier. Proc Natl Acad Sci U S A. 2013;110:2999–3004. doi:10.1073/pnas.1222742110.
   PubMed Web of Science ®Google Scholar
• Boado RJ, Hui EK-W, Lu JZ, Pardridge WM. Glycemic control and chronic dosing of rhesus monkeys with a fusion protein of iduronidase and a monoclonal antibody against the human insulin receptor. Drug Metab Dispos. 2012;40:2021–2025. doi:10.1124/dmd.112.046375.
   PubMed Web of Science ®Google Scholar
• Xiao G, Gan LS. Receptor-mediated endocytosis and brain delivery of therapeutic biologics. Int J Cell Biol. 2013;2013:703545. doi:10.1155/2013/703545.
   PubMedGoogle Scholar
• Chakravarty R, Goel S, Cai W. Nanobody: The “Magic Bullet” for molecular imaging? Theranostics. 2014;4(4):386–398 doi:10.7150/thno.8006.
   PubMed Web of Science ®Google Scholar
• Balkwill FR. The chemokine system and cancer. J. Pathol. 2012;226:148–157 doi:10.1002/path.3029.
   PubMed Web of Science ®Google Scholar
• Chatalic KLS, Veldhoven-Zweistra J, Bolkestein M, Hoeben S, Koning GA, Boerman OC, et al. A novel 111In-labeled anti–prostate-specific membrane antigen nanobody for targeted SPECT/CT imaging of prostate cancer. J Nucl Med. 2015;56:1094–1099 doi:10.2967/jnumed.115.156729.
   PubMed Web of Science ®Google Scholar
• Ametamey SM, Honer M, Schubiger PA. Molecular imaging with PET. Chem Rev. 2008;108:1501–1516. doi:10.1021/cr0782426.
   PubMed Web of Science ®Google Scholar
• Alauddin MM. Positron emission tomography (PET) imaging with 18 F-based radiotracers. Am J Nucl Med Mol Imaging. 2012;2:55–76.
   PubMedGoogle Scholar
• Holland JP, Cumming P, Vasdev N. PET radiopharmaceuticals for probing enzymes in the brain. Am J Nucl Med Mol Imaging. 2013;3:194–216.
   PubMedGoogle Scholar
• Vosjan MJ, Perk LR, Roovers RC, Visser GW, Stigter-van Walsum M, van Bergen En Henegouwen PM, et al. Facile labelling of an anti-epidermal growth factor receptor nanobody with Ga-68 via a novel bifunctional desferal chelate for immuno-PET. Eur J Nucl Med Mol Imaging. 2011;38(4):753–763. doi:10.1007/s00259-010-1700-1.
   PubMed Web of Science ®Google Scholar
• Sukhanova A, Even-Desrumeaux K, Kisserli A, Tabary T, Reveil B, Millot JM, Chames P, Baty D, Artemyev M, Oleinikov V, et al. Oriented conjugates of single-domain antibodies and quantum dots: toward a new generation of ultrasmall diagnostic nanoprobes. Nanomedicine. 2012;8:516–525. doi:10.1016/j.nano.2011.07.007.
   PubMed Web of Science ®Google Scholar
• Gainkam LO, Caveliers V, Devoogdt N, Vanhove C, Xavier C, Boerman O, et al. Localization, mechanism and reduction of renal retention of technetium-99 m labeled epidermal growth factor receptor-specific nanobody in mice. Contrast Media Mol Imaging. 2011;6:85–92 doi:10.1002/cmmi.408.
   PubMed Web of Science ®Google Scholar
• Huang L, Gainkam LO, Caveliers V, Vanhove C, Keyaerts M, De Baetselier P, Bossuyt A, Revets H, Lahoutte T. SPECT imaging with 99mTc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression. Mol Imaging Biol. 2008;10(3):167–175. doi:10.1007/s11307-008-0133-8.
   PubMed Web of Science ®Google Scholar
• Gainkam LO, Huang L, Caveliers V, Keyaerts M, Hernot S, Vaneycken I, Vanhove C, Revets H, De Baetselier P, Lahoutte T. Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT. J Nucl Med. 2008;49(5):788–795. doi:10.2967/jnumed.107.048538.
   PubMed Web of Science ®Google Scholar
• Newkirk MM, Novick J, Stevenson MM, Fournier MJ, Apostolakos P. Differential clearance of glycoforms of IgG in normal and autoimmune-prone mice. Clin Exp Immunol. 1996;106(2):259–264 doi:10.1046/j.1365-2249.1996.d01-847.x.
   PubMed Web of Science ®Google Scholar
• Chapman AP, Antoniw P, Spitali M, West S, Stephens S, King DJ. Therapeutic antibody fragments with prolonged in vivo half-lives. Nat Biotechnol. 1999;17(8):780–783 doi:10.1038/11717.
   PubMed Web of Science ®Google Scholar
• Quartarone E, Alonci A, Allegra A, Bellomo G, Calabrò L, D'Angelo A, Del Fabro V, Grasso A, Cincotta M, Musolino C. Differential levels of soluble angiopoietin-2 and Tie-2 in patients with haematological malignancies. Eur J Haematol. 2006;77(6):480–485. doi:10.1111/j.0902-4441.2006.t01-1-EJH2795.x.
   PubMed Web of Science ®Google Scholar
• Musolino C, Alonci A, Bellomo G, Loteta B, Quartarone E, Gangemi D, Massara E, Calabrò L. Levels of soluble angiogenin in chronic myeloid malignancies: clinical implications. Eur J Haematol. 2004;72(6):416–419 doi:10.1111/j.1600-0609.2004.00253.x.
   PubMed Web of Science ®Google Scholar
• Farajpour Z, Rahbarizadeh F, Kazemi B, Ahmadvand D. A nanobody directed to a functional epitope on VEGF, as a novel strategy for cancer treatment. Biochem Biophys Res Communications. 2014;446:132–136 doi:10.1016/j.bbrc.2014.02.069.
   PubMed Web of Science ®Google Scholar
• Behdani M, Zeinali S, Karimipour M, Khanahmad H, Schoonooghe S, Aslemarz A, Seyed N, Moazami-Godarzi R, Baniahmad F, Habibi-Anbouhi M, et al. Development of VEGFR2-specific Nanobody Pseudomonas exotoxin A conjugated to provide efficient inhibition of tumor cell growth. New Biotechnol. 2013;30:205–209 doi:10.1016/j.nbt.2012.09.002.
   PubMed Web of Science ®Google Scholar
• Van Heeke G, Allosery K, De Brabandere V, De Smedt T, Detalle L, de Fougerolles A. Nanobodies® as inhaled biotherapeutics for lung diseases. Pharmacol Ther. 2017;169:47–56. doi:10.1016/j.pharmthera.2016.06.012.
   PubMed Web of Science ®Google Scholar
• Detalle L, Stohr T, Palomo C, Piedra PA, Gilbert BE, Mas V, Millar A, Power UF, Stortelers C, Allosery K, et al. Generation and Characterization of ALX-0171, a potent novel therapeutic nanobody for the treatment of respiratory syncytial virus infection. Antimicrob Agents Chemother. 2015;60:6–13. doi:10.1128/AAC.01802-15.
   PubMed Web of Science ®Google Scholar
• Wang Y, Fan Z, Shao L, Kong X, Hou X, Tian D, Sun Y, Xiao Y, Yu L. Nanobody-derived nanobiotechnology tool kits for diverse biomedical and biotechnology applications. Int J Nanomed. 2016;11:3287–3303. doi:10.2147/IJN.S107194.
   PubMed Web of Science ®Google Scholar
• Allegra A, Innao V, Gerace D, Vaddinelli D, Musolino C. Adoptive immunotherapy for hematological malignancies: Current status and new insights in chimeric antigen receptor T cells. Blood Cells Mol Dis. 2016;62:49–63. doi:10.1016/j.bcmd.2016.11.001.
   PubMed Web of Science ®Google Scholar
• Bannas P, Hambach J, Koch-Nolte F. Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics. Front Immunol. 2017;8:1603 doi:10.3389/fimmu.2017.01603.
   PubMed Web of Science ®Google Scholar
• Kontermann RE. Strategies for extended serum half-life of protein therapeutics. Curr Opin Biotechnol. 2011;22(6):868–876. doi:10.1016/j.copbio.2011.06.012.
   PubMed Web of Science ®Google Scholar